IFUL Insightful Corp (MM)

Insightful Corporation (NASDAQ:IFUL), a leading provider of predictive analytics and reporting solutions, today announced building momentum with large life sciences customers, including both new and expanding engagements over the past 12 months to integrate cutting-edge analytics and graphics into all phases of the drug development life cycle. Insightful counts a majority of the world�s leading pharmaceutical companies as customers, including Pfizer, Inc., AstraZeneca International, Johnson & Johnson, and Hoffman-La Roche, Inc. During the past 12 months, each of these four companies and many of the other leading pharmaceutical companies started new life sciences solutions projects with Insightful, expanded existing projects, or purchased more software licenses from Insightful. Pfizer, Inc. has signed an agreement to deploy S-PLUS predictive analytics software within the company. Insightful�s agreement with Pfizer is based on software license and maintenance fees. Life Sciences Solutions Provide the Knowledge to Act� Insightful provides life sciences organizations with the knowledge they need to drive faster, better decisions with specialized analytics, graphics and reporting formats. Insightful offers software and service solutions in clinical graphics, PK/PD reporting, clinical data review, innovative trial design, and safety data mining. These solutions are designed to act in concert with existing data management and workflow systems within validated environments to speed the analysis and reporting processes, to increase the likelihood of discerning safety and efficacy signals earlier in the development lifecycle thus decreasing our customers� product development costs and time to market. �The agreement with Pfizer, which was signed in December, was one of several with large life sciences companies over the past 12 months, which we believe reflects pharmaceutical companies� demand for faster, better and more cost-effective ways to analyze their data and report their results in all phases of the drug development lifecycle,� said Jeff Coombs, president and CEO of Insightful. �The analytic rigor and graphic superiority of our S-PLUS platform for pre-clinical, clinical, and regulatory submissions have been recognized by our customers as setting a standard of excellence in the industry.� ABOUT INSIGHTFUL Insightful Corporation (NASDAQ:IFUL) is a provider of predictive analytics and reporting solutions that gives companies the knowledge to act�. Insightful products S-PLUS�, Insightful Miner�, S-PLUS� Server and InFact� allow companies to perform sophisticated statistical data analysis, data mining and create high-quality graphics from numeric and text data. The company has been delivering industry-leading, high-ROI solutions to thousands of companies in financial services, life sciences, biotechnology, telecommunications, and manufacturing, plus government and research institutions. Headquartered in Seattle, Insightful has offices in New York, North Carolina, France, Switzerland, and the United Kingdom, with distributors around the world. For more information, visit www.insightful.com, email info@insightful.com or call 800-569-0123. Note to Investors -- Forward-Looking Statements This press release contains forward-looking statements, including statements about our customers� plans for deploying our products and the expected benefits of our solutions, including the ability of our products to improve the quality and timeliness of predictive analytics and quantitative research. Forward-looking statements are based on the judgment and opinions of management at the time the statements are made. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from those expressed or implied by the forward-looking statements for a number of reasons, including, without limitation, the risk that our products to not perform as expected and the risks associated with defects or errors in our products. More detailed information regarding these and other factors that could affect actual results is set forth in our filings with the Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-QSB. You should not unduly rely on these forward-looking statements, which apply only as of the date of this release. We undertake no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of anticipated events.